Advisor Group’s Arcadia Biosciences RKDA Stock Holding History

Advisor Group’s Portfolio RKDA Stock Details RKDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-50	Closed	-$9K	–	5429
2019 Q3	$9K	Hold	50	–	–	﹤0.01%	4406
2019 Q2	$6K	Hold	50	–	–	﹤0.01%	4614
2019 Q1	$14K	Buy	50 +25	+100%	+$5.22K	﹤0.01%	4190
2018 Q4	$3K	Hold	25	–	–	﹤0.01%	4728
2018 Q3	$5K	Sell	25 -20	-44%	-$5.02K	﹤0.01%	4608
2018 Q2	$15K	Buy	+45	New	+$24.6K	﹤0.01%	3871

Other funds holding RKDA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Advisor Group's RKDA Position: Q4 2019 in Review

Advisor Group sold out of Arcadia Biosciences (RKDA) in Q4 2019, closing a stake of 50 shares — an estimated $9K sold.

Advisor Group first reported a position in RKDA in Q2 2018 and held it in 6 quarters. The position peaked at $15K in Q2 2018. 14 funds tracked by Wall St. Rank hold RKDA as of Q4 2019.

Advisor Group reported no remaining Arcadia Biosciences position as of Q4 2019 after selling out during the quarter.
Advisor Group sold 50 Arcadia Biosciences shares in Q4 2019, an estimated $9K.
Advisor Group first reported a position in Arcadia Biosciences in Q2 2018 and held it in 6 quarters.
Advisor Group's Arcadia Biosciences position peaked at $15K in Q2 2018.
14 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.